A new bipartisan bill introduced by Sens. Chuck Grassley (R-Iowa) and Ron Wyden (D-Oregon) looks to tighten regulations around Medicaid rebates to stop drugmakers from overcharging U.S. taxpayers, The Hill reports.
The proposed legislation would provide the Department of Health and Human Services with new abilities to reclassify a drug and retrieve rebates when a drug manufacturer intentionally misclassifies a treatment to pay lower rebates, according to the report.
Both lawmakers made mention of Mylan, which deliberately classified the EpiPen as a generic when it was, in fact, a brand drug.
“While families struggle to afford medicines like EpiPen, drug makers are busy manipulating the system to squeeze taxpayers even more,” Wyden said in a statement.